Mobile website
Expert Forum
Edg/LPAR mediated LPA: A novel target for tumor targeting therapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Lysophosphatidic acid (LPA) is a naturally occurring phospholipid with diverse effects on various cells, ranging from cellular morphology alterations to cellular function changes such as induction of cell proliferation, survival, drug resistance and motility. Like many other biomediators, LPA interacts with cells through specific cell surface receptors (G protein-coupled receptors). Edg-2/LPA1, Edg-4/LPA2 and Edg-7/LPA3, named as endothelial differentiation gene or lysophospholipidic receptor subfamily (Edg/LPA subfamily), are three most common LPA receptors. LPA plays a critical role as a general growth, survival and pro-angiogenic factor in the regulation of pathophysiological processes in vivo and in vitro. Recent reports in the literature suggest that abnormalities in LPA metabolism and Edg/LPA receptors function in cancer patients may contribute to the development and progression of the disease. Thus, LPA and its receptors might be potential targets for clinical cancer diagnosis and therapy. Herein we review the function and mechanism of LPA and its receptors in the development and progression of tumors with focus on human pancreatic cancer, and also clinical diagnosis and treatment has been evaluated.
Keywords:
Project Supported:
Project supported by the Foundation of “Science and Education Promoting Health Engineering” of Health Bureaus for Medical Leading Talents and Innovation Teams of Jiangsu Province（No.2011-15）, the Major Medical Science and Technology Development Program of Nanjing Medical University (No. 08NMUZ042), and the Major Medical Science and Technology Development Program of Nanjing (No. ZKX09007)
Clc Number:
